Your browser doesn't support javascript.
loading
Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy.
Shukla, Shakti D; Taylor, Steven L; Gibson, Peter G; Barker, Daniel; Upham, John W; Yang, Ian A; Reynolds, Paul N; Hodge, Sandra; James, Alan L; Rogers, Geraint B; Simpson, Jodie L.
Affiliation
  • Shukla SD; Faculty of Health and Medicine, The University of Newcastle Priority Research Centre for Asthma and Respiratory Disease, Newcastle, New South Wales, Australia.
  • Taylor SL; Microbiome and Host Health, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
  • Gibson PG; SAHMRI Microbiome Research Laboratory, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
  • Barker D; Faculty of Health and Medicine, The University of Newcastle Priority Research Centre for Asthma and Respiratory Disease, Newcastle, New South Wales, Australia.
  • Upham JW; Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Yang IA; Faculty of Health and Medicine, The University of Newcastle Priority Research Centre for Asthma and Respiratory Disease, Newcastle, New South Wales, Australia.
  • Reynolds PN; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Hodge S; Translational Research Institute, Brisbane, QLD, Australia.
  • James AL; Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Rogers GB; Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, QLD, Australia.
  • Simpson JL; Department of Respiratory Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Thorax ; 76(7): 733-736, 2021 07.
Article in En | MEDLINE | ID: mdl-33414242
ABSTRACT
Add-on azithromycin (AZM) significantly reduces exacerbations in poorly controlled asthma irrespective of disease phenotype. In a predefined substudy of the original AMAZES protocol (500 mg, three times a week for 48 weeks), we report that AZM treatment reduces key sputum inflammatory proteins (interleukin (IL)-6, IL-1ß and extracellular DNA), which is more evident in non-eosinophilic asthma (NEA). Moreover, AZM reduced Haemophilus influenzae load only in NEA. Our data support the anti-inflammatory effects of AZM in poorly controlled asthma. Prospective studies are required to identify patients that derive greatest benefit from AZM add-on therapy.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Sputum / Cytokines / Azithromycin Type of study: Guideline / Observational_studies Limits: Humans Language: En Journal: Thorax Year: 2021 Type: Article Affiliation country: Australia
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Sputum / Cytokines / Azithromycin Type of study: Guideline / Observational_studies Limits: Humans Language: En Journal: Thorax Year: 2021 Type: Article Affiliation country: Australia